 |
市場調查報告書
商品編碼
1684618
心絞痛藥物市場機會、成長動力、產業趨勢分析與預測 2025 - 2034Angina Pectoris Drugs Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034 |
||||||
2024 年全球心絞痛藥物市場價值為 123 億美元，預計 2025 年至 2034 年期間將以 4.1% 的複合年成長率穩步成長。與生活方式相關的健康風險（如不良飲食、缺乏運動、吸煙、壓力和肥胖）的增加導致心絞痛等心血管疾病發病率的上升。隨著心臟病盛行率不斷上升，對有效治療方案的需求也不斷擴大。醫療保健產業正在採取創新措施，旨在改善心絞痛患者的生活品質。此外，醫療保健意識的提高、醫療保健基礎設施的改善以及藥物可近性的提高等因素進一步推動了該市場的成長。
市場按類型分類，穩定型心絞痛佔據主導地位，在 2024 年佔 51.3% 的佔有率。鑑於穩定型心絞痛的普遍性，它對市場有重大影響，尤其是因為它常見於冠狀動脈疾病患者。硝酸鹽、BETA受體阻斷劑和鈣通道阻斷劑等成熟治療方案的出現確保了對病情的有效管理，並鼓勵患者和醫療保健專業人員廣泛使用它們。
| 市場範圍 | |
|---|---|
| 起始年份 | 2024 |
| 預測年份 | 2025-2034 |
| 起始值 | 123億美元 |
| 預測值 | 181億美元 |
| 複合年成長率 | 4.1％ |
根據給藥途徑，心絞痛藥物市場分為口服、注射和外用製劑。口服藥物在市場佔有率方面佔據領先地位，預計整個預測期內將以 4% 的複合年成長率成長。口服藥物，例如BETA受體阻斷劑、硝酸鹽和鈣通道阻斷劑，由於其方便且價格便宜而受到人們的普遍青睞。它們通常是治療心絞痛的首選藥物，因為它們可以輕鬆使用而不需要頻繁地去醫療機構。這些治療方法的製造和分銷成本較低，對患者和提供者來說都是有吸引力的選擇。鑑於心絞痛需要長期治療，口服藥物是日常使用的理想選擇，並且可以顯著提高患者的依從性。
美國心絞痛藥物市場價值 2024 年為 46 億美元，在推動整體市場成長方面發揮關鍵作用。該國心絞痛盛行率不斷上升，加上對更有效治療方法的需求，刺激了市場擴張。此外，美國繼續在醫學研究和創新方面處於領先地位，心絞痛治療領域不斷發展，包括先進的聯合療法和增強型BETA受體阻斷劑，進一步加速了市場的成長。藥物開發的持續進步，加上該國強大的醫療保健基礎設施，使美國成為全球市場未來成功的重要貢獻者。
目錄
第 1 章：方法論與範圍
第 2 章：執行摘要
第 3 章：產業洞察
- 產業生態系統分析
- 產業衝擊力
- 成長動力
- 心血管疾病盛行率上升
- 藥物開發的進展
- 與生活方式相關的危險因子增多
- 產業陷阱與挑戰
- 與藥物相關的副作用
- 微創手術的採用日益廣泛
- 成長動力
- 成長潛力分析
- 監管格局
- 管道分析
- 波特的分析
- PESTEL 分析
第4章：競爭格局
- 介紹
- 公司矩陣分析
- 主要市場參與者的競爭分析
- 競爭定位矩陣
- 策略儀表板
第 5 章：市場估計與預測：按類型，2021 年至 2034 年
- 主要趨勢
- 穩定型心絞痛
- 不穩定性心絞痛
- 微血管性心絞痛
- 心絞痛
第 6 章：市場估計與預測：按藥物類別，2021 年至 2034 年
- 主要趨勢
- BETA受體阻斷劑
- 硝酸鹽
- 抗血小板
- 鈣通道阻斷劑
- 抗凝血劑
- 血管緊張素轉換酶 (ACE) 抑制劑
- 其他藥物類別
第 7 章：市場估計與預測：按管理路線，2021 年至 2034 年
- 主要趨勢
- 口服
- 注射劑
- 主題
第 8 章：市場估計與預測：按配銷通路，2021 年至 2034 年
- 主要趨勢
- 醫院藥房
- 零售藥局
- 網路藥局
第 9 章：市場估計與預測：按地區，2021 年至 2034 年
- 主要趨勢
- 北美洲
- 美國
- 加拿大
- 歐洲
- 德國
- 英國
- 法國
- 義大利
- 西班牙
- 荷蘭
- 亞太地區
- 中國
- 日本
- 印度
- 澳洲
- 韓國
- 拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 中東和非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
第10章：公司簡介
- AdvaCare Pharma
- Amgen
- AstraZeneca
- Bayer
- Boehringer Ingelheim International
- Eli Lilly and Company
- Gilead Sciences
- GlaxoSmithKline
- Merck
- Novartis
- Otsuka Pharmaceutical
- Pfizer
- Sanofi
The Global Angina Pectoris Drugs Market was valued at USD 12.3 billion in 2024 and is expected to grow at a steady rate of 4.1% CAGR between 2025 and 2034. This growth is largely driven by the increasing prevalence of cardiovascular diseases, significant advancements in therapeutic treatments, and a rapidly aging population. The rise in lifestyle-related health risks-such as poor diets, lack of physical activity, smoking, stress, and obesity-has contributed to a higher incidence of cardiovascular conditions, including angina. As the prevalence of heart disease continues to rise, the demand for effective treatment options is also expanding. The healthcare industry is responding with innovations aimed at improving the quality of life for patients dealing with angina. Additionally, factors such as rising healthcare awareness, improved healthcare infrastructure, and increasing accessibility to medication are further fueling the growth of this market.
The market is categorized by type, with stable angina leading the segment, accounting for a 51.3% share in 2024. This form of angina is the most common and is characterized by chest pain that is predictable and often triggered by physical exertion or emotional stress. Given its prevalence, stable angina has a significant impact on the market, especially as it is commonly found in patients with coronary artery disease. The availability of well-established treatment options-such as nitrates, beta-blockers, and calcium channel blockers-ensures efficient management of the condition, encouraging their widespread use among patients and healthcare professionals alike.
| Market Scope | |
|---|---|
| Start Year | 2024 |
| Forecast Year | 2025-2034 |
| Start Value | $12.3 Billion |
| Forecast Value | $18.1 Billion |
| CAGR | 4.1% |
In terms of administration route, the angina pectoris drug market is divided into oral, injectable, and topical formulations. Oral medications take the lead in terms of market share and are projected to grow at a 4% CAGR throughout the forecast period. Oral drugs, such as beta-blockers, nitrates, and calcium channel blockers, are commonly preferred due to their convenience and affordability. They are often the first choice for treating angina, as they can be easily administered without the need for frequent visits to healthcare facilities. These treatments offer lower manufacturing and distribution costs, making them an attractive option for both patients and providers. Given that angina pectoris requires long-term treatment, oral medications are ideal for daily use and can significantly enhance patient compliance.
The U.S. angina pectoris drug market, valued at USD 4.6 billion in 2024, plays a critical role in driving the overall market growth. The country's increasing prevalence of angina, combined with a demand for more effective therapies, has spurred market expansion. Moreover, the U.S. continues to be a leader in medical research and innovation, with ongoing developments in angina treatments, including advanced combination therapies and enhanced beta blockers, further accelerating market growth. This consistent advancement in drug development, coupled with the country's robust healthcare infrastructure, positions the U.S. as a significant contributor to the future success of the global market.
Table of Contents
Chapter 1 Methodology and Scope
- 1.1 Market scope and definition
- 1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
- 1.3 Base estimates and calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
- 1.4 Forecast model
- 1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources
Chapter 2 Executive Summary
- 2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
- 3.1 Industry ecosystem analysis
- 3.2 Industry impact forces
- 3.2.1 Growth drivers
- 3.2.1.1 Rising prevalence of cardiovascular diseases
- 3.2.1.2 Advancements in drug development
- 3.2.1.3 Increasing lifestyle-related risk factors
- 3.2.2 Industry pitfalls and challenges
- 3.2.2.1 Side effects associated with the drugs
- 3.2.2.2 Growing adoption of minimally invasive surgeries
- 3.2.1 Growth drivers
- 3.3 Growth potential analysis
- 3.4 Regulatory landscape
- 3.5 Pipeline analysis
- 3.6 Porter's analysis
- 3.7 PESTEL analysis
Chapter 4 Competitive Landscape, 2024
- 4.1 Introduction
- 4.2 Company matrix analysis
- 4.3 Competitive analysis of major market players
- 4.4 Competitive positioning matrix
- 4.5 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Type, 2021 – 2034 ($ Mn)
- 5.1 Key trends
- 5.2 Stable angina
- 5.3 Unstable angina
- 5.4 Microvascular angina
- 5.5 Prinzmetal angina
Chapter 6 Market Estimates and Forecast, By Drug Class, 2021 – 2034 ($ Mn)
- 6.1 Key trends
- 6.2 Beta blockers
- 6.3 Nitrates
- 6.4 Anti-platelets
- 6.5 Calcium channel blockers
- 6.6 Anticoagulants
- 6.7 ACE inhibitors
- 6.8 Other drug classes
Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 – 2034 ($ Mn)
- 7.1 Key trends
- 7.2 Oral
- 7.3 Injectable
- 7.4 Topical
Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 – 2034 ($ Mn)
- 8.1 Key trends
- 8.2 Hospital pharmacies
- 8.3 Retail pharmacies
- 8.4 Online pharmacies
Chapter 9 Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)
- 9.1 Key trends
- 9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
- 9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Italy
- 9.3.5 Spain
- 9.3.6 Netherlands
- 9.4 Asia Pacific
- 9.4.1 China
- 9.4.2 Japan
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 South Korea
- 9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Argentina
- 9.6 Middle East and Africa
- 9.6.1 South Africa
- 9.6.2 Saudi Arabia
- 9.6.3 UAE
Chapter 10 Company Profiles
- 10.1 AdvaCare Pharma
- 10.2 Amgen
- 10.3 AstraZeneca
- 10.4 Bayer
- 10.5 Boehringer Ingelheim International
- 10.6 Eli Lilly and Company
- 10.7 Gilead Sciences
- 10.8 GlaxoSmithKline
- 10.9 Merck
- 10.10 Novartis
- 10.11 Otsuka Pharmaceutical
- 10.12 Pfizer
- 10.13 Sanofi
